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SUMMARY
We report that TG101348, a selective small-molecule inhibitor of JAK2 with an in vitro IC50 of 3 nM, shows
therapeutic efficacy in a murine model of myeloproliferative disease induced by the JAK2V617Fmutation. In
treated animals, there was a statistically significant reduction in hematocrit and leukocyte count, a dose-de-
pendent reduction/elimination of extramedullary hematopoiesis, and, at least in some instances, evidence for
attenuation of myelofibrosis. There were no apparent toxicities and no effect on T cell number. In vivo re-
sponses were correlated with surrogate endpoints, including reduction/elimination of JAK2V617F disease
burden assessed by quantitative genomic PCR, suppression of endogenous erythroid colony formation,
and in vivo inhibition of JAK-STAT signal transduction as assessed by flow cytometric measurement of phos-
phorylated Stat5.INTRODUCTION
The prevalence of myeloproliferative diseases (MPD) polycythe-
mia vera (PV), essential thrombocytosis (ET), and primary myelo-
fibrosis (PMF) in the United States has been estimated at
80,000–100,000 cases, with 2–5 new cases per 100,000 per
year. These MPD collectively have a higher prevalence than
BCR-ABL-positive chronic myelogenous leukemia (CML). In ad-
dition to thrombotic events and bleeding complications, these
patients are at risk for progression to acute myelogenous leuke-
mia, and PV and ET patients are at risk for progression to myelo-
fibrosis. Current therapies are similar to those used to treat BCR-ABL-positive chronic myeloid leukemia prior to the development
of the imatinib and include hydroxyurea, and interferon-alpha
(Kiladjian et al., 2006; Tefferi et al., 2006). In addition, phlebotomy
may be used to induce iron deficiency to control polycythemia in
patients with PV, and anagrelide may have benefit in selected
MPD patients with thrombocytosis (Harrison et al., 2005). How-
ever, there are currently no molecularly targeted therapies avail-
able for treatment of this large cohort of patients that would be
analogous to use of imatinib for treatment of CML (Druker
et al., 2001a).
The JAK2V617F mutation is observed in 99% of PV patients
and approximately half of the patients with myelofibrosis andSIGNIFICANCE
The JAK2V617F mutation is present in the majority of cases of myeloproliferative disease (MPD), including polycythemia
vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), and is an attractive candidate for molecularly
targeted therapy. However, the potential toxicities of JAK2 inhibition in vivo and identification of appropriate surrogate end-
points for response are challenges that may limit clinical usefulness in treatment of these relatively indolent diseases. We
tested the activity of a clinical lead compound, TG101348, in a murine model of JAK2V617F-induced myeloproliferative dis-
ease.We observed that TG101348 is safe and effective in treatment ofMPD in thismodel system and identify surrogate end-
points for response that may be of value in clinical trials in humans.Cancer Cell 13, 311–320, April 2008 ª2008 Elsevier Inc. 311
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Efficacy of TG101348 in a Murine Model of PVessential thrombocythemia, respectively (Baxter et al., 2005;
James et al., 2005; Kralovics et al., 2005; Levine et al., 2005). Ex-
pression of JAK2V617F confers factor-independent growth to
various hematopoietic cell lines, including Ba/F3, 32D, and
FDCP (James et al., 2005; Levine et al., 2005), and does so
most efficiently in the presence of Type I cytokine receptors
that lack a common chain, such as the erythropoietin, thrombo-
poietin, and G-CSF receptors, respectively (Lu et al., 2005). In
each of these cellular contexts and in human HEL cells that
also harbor the JAK2V617F allele, apoptotic cell death is in-
duced by small molecule inhibitors of JAK2 (Levine et al.,
2005). Thus, hematopoietic cells transformed by JAK2V617F
exhibit oncogene dependence that has been observed in cells
transformed by BCR-ABL. These findings suggest that
JAK2V617F may be a valid target for therapeutic intervention in
MPD associated with this mutation. Of note, in vitro data suggest
that the rare PV patients with exon 12 activating mutations in
JAK2 (Scott et al., 2007) and the 5% of PMF and ET patients
that have the MPLW515L/K-activating mutation might also be
targeted with JAK2 inhibitors (Pikman et al., 2006).
Here, we report efficacy of a small-molecule JAK2 inhibitor,
TG101348, with suitable characteristics for in vivo use in hu-
mans, in a murine model of disease (Wernig et al., 2006). Further-
more, we utilize this model to develop and validate surrogate
endpoints for response in treated animals that include assess-
ment of genomic burden of disease using quantitative PCR, ab-
rogation of erythropoietin-independent colony formation that is
a hallmark of the MPD, and inactivation of STAT5 as a critical ef-
fector of JAK2V617F as assessed by phosphoflow cytometry.
We also observe that the inhibitor has minimal impact on T cell
number with dosing regimens that impact the disease pheno-
type. TG101348 is well tolerated, is an effective therapeutic
agent in a murine model of disease, and may be suitable for
the initiation of clinical trials in humans with JAK2V617F associ-
ated MPD.
RESULTS
In Vitro Characteristics of TG101348
TG101348 is a small-molecule, ATP-competitive inhibitor de-
signed and synthesized using structure-based drug design
methods to inhibit JAK2, but not other closely related kinases
(Figure S1 available online; Table 1; Table S1). TG101348 had
a high degree of kinase selectivity for JAK2. For example,
TG101348 had an IC50 300-fold higher for the closely related
JAK3 and was a less potent inhibitor of the JAK1 and TYK2 family
members. The activity of TG101348 was evaluated in a variety of
cell-based assays. TG101348 inhibited proliferation of a human
erythroblast leukemia (HEL) cell line that harbors the JAK2V617F
mutation, as well as a murine pro-B cell line expressing human
JAK2V617F (Ba/F3 JAK2V617F), with an IC50 value of approxi-
mately 300 nM for either line (Figure 1A; Table S2). Proliferation
of parental Ba/F3 cells was inhibited to a comparable level,
with an IC50 value of 420 nM, consistent with the essential
role of IL-3-dependent signaling in the parental cell line
(Figure S2A). Exposure of these cells to TG101348 reduced
STAT5 phosphorylation at concentrations that parallel the con-
centrations required to inhibit cell proliferation (Figure 1B). In
accordance with the above results and the premise that these312 Cancer Cell 13, 311–320, April 2008 ª2008 Elsevier Inc.cells require JAK2 activity for both proliferation and survival,
TG101348 induced apoptosis in both HEL and Ba/F3
JAK2V617F cells in a dose-dependent manner (Figure 1C). In
contrast, TG101348 did not show proapoptotic activity in control
normal human dermal fibroblasts at concentrations up to 10 mM,
and the antiproliferative IC50 against fibroblasts was >5,000 nM.
(Figure S2B). These data indicate that TG101348 is a potent and
highly selective inhibitor of JAK2 kinase in cell-based assays of
transformation.
Pharmacokinetic Properties of TG101348
in C57Bl/6 Mice
The pharmacokinetic parameters of TG101348 were evaluated
in C57Bl/6 mice following single oral administration of doses
ranging from 30 mg/kg to 200 mg/kg. Maximum plasma concen-
trations (Cmax) of 0.68, 3.58, and 4.28 mM were observed at 3 hr
postdose following oral gavage of 30, 100, and 200 mg/kg, re-
spectively (Figure 1D). Following oral administration of
TG101348, the total plasma exposure (AUC) increased linearly
with respect to dose. At 7 and 24 hr postdose, the mean plasma
concentrations were 0.483 and 0.02 mM for a 100 mg/kg dose,
indicating that sustained plasma concentrations above the cellu-
lar IC50 could be achieved with twice daily (bid) administration.
The steady-state plasma concentrations following bid admin-
istration showed no appreciable plasma accumulation. Based
on the linearity and predictability of the TG101348 oral pharma-
cokinetics over dose range of 30 to 200 mg/kg, bid doses of 60
and 120 mg/kg were selected for evaluation in the murine model
of polycythemia vera.
Efficacy of TG101348 in a Murine Model
of JAK2V617F-Induced Polycythemia Vera
Study Design
We tested the efficacy of TG101348 in a murine bone marrow
transplant assay of established polycythemia vera that recapitu-
lates many of the features of the human disease. In brief, primary
hematopoietic cells were transduced with a murine ecotropic
retrovirus harboring the mutant JAK2V617F allele, and on day
26 after bone marrow transplantation into lethally irradiated syn-
geneic recipient mice, the development of polycythemia was as-
sessed by differential peripheral blood count. All mice developed
erythrocytosis with average hematocritsR 70% prior to initiation
of treatment on day 27. The animals were divided into treatment
or vehicle control groups (n = 20 mice/group). Because the
Table 1. TG101348 Is JAK Family Selective and Relatively
Specific
Kinase Selectivity Profile of TG101348
Primary Target JAK Family Kinases
Kinase Enzyme IC50 (nM) Kinase Fold Selectivity
a
JAK2 3 JAK2 1
JAK2 V617F 3 JAK3 334
Flt3 15 JAK1 35
Ret 48 Tyk2 135
No other tested kinase with IC50 < 50 nM.
a Fold selectivity over JAK2.
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Efficacy of TG101348 in a Murine Model of PVFigure 1. In Vitro Activities and Pharmacokinetics of TG101348
(A) HEL and Ba/F3 JAK2V617F cells were incubated with indicated concentrations of TG101348, and their proliferation was determined.
(B) HEL and Ba/F3 JAK2V617F cells were incubated with 0.1, 0.3, 1, 3, and 10 mM of TG101348, and the phospho-Stat5 status was assessed.
(C) TG101348 eliminated malignant cells by induction of apoptosis as shown by increased DNA fragmentation in a dose-dependent manner.
(D) C57Bl/6 mice were dosed with 30 mg/kg, 100 mg/kg, and 200 mg/kg of TG101348, and serum concentrations of the drug were assessed at 30 min, 1 hr, 3 hr,
5 hr, 7 hr, and 24 hr posttreatment. The error bars represent the mean ± SD.half-life of murine erythrocytes is on the order of 40–50 days,
treatment trials were employed in animals that were treated
for 42 days to assess the effect of treatment on polycythemia,
as well as to assess potential for hematologic toxicities including
T cell immunosuppression and other toxicities. TG101348 was
administered by oral gavage at 60 mg/kg or 120 mg/kg bid for
42 days, whereas the control group received vehicle only. Mori-
bund mice were sacrificed during the trial, and all remaining mice
were sacrificed at trial endpoint. Three independent trials were
performed where mice were treated with TG101348 or vehicle,
involving a total of 56 placebo and 112 drug-treated mice with
JAK2V617F-induced polycythemia.
Survival and Response of Treated Animals
During the time course of the study, six animals died in the pla-
cebo group, and one animal in the 60 mg/kg drug group at day
18, whereas all animals treated with 120 mg/kg of TG101348
were all alive at study endpoint (Figure 2A). Retro-orbital sam-
pling of peripheral blood demonstrated a mean reduction in he-
matocrit of 5.1% (hct 80.9%) in animals treated with 60 mg/kg
(p < 0.05) and 17.9% (hct 68.1%) in animals treated with 120
mg/kg (p < 0.0001) compared to placebo (hct 86%) by study
endpoint at day 42. Thus, there was a dose-dependent reduction
in polycythemia (Figure 2C). In addition, there was marked dose-
dependent reduction in splenomegaly of treated animals com-
pared to vehicle-treated controls (Figures 2B and 2C).
As a correlate of reduction in spleen weights, there was also
clear evidence of dose-dependent histopathologic response as
assessed by the degree of extramedullary hematopoiesis inspleens and livers of treated animals (Figures 2Da–2Di). Histo-
pathological analysis of spleens from PV animals treated with ve-
hicle showed effacement of normal splenic architecture and
a significant expansion of the red pulp by a predominant popu-
lation of erythroid elements, mature myeloid cells, and clusters
of dysplastic megakaryocytes. In contrast, animals treated with
120 mg/kg showed normal splenic architecture, with small resid-
ual pockets of erythroid precursors (Figures 2Da–2Df). In
addition, hepatic sections of mice treated with placebo demon-
strated extramedullary hematopoiesis consisting of infiltrates of
maturing myeloid and erythroid elements that was completely
abrogated upon treatment with TG101348 in both the 60 mg/
kg and 120 mg/kg treatment arms (Figures 2Dg–2Gi). As ex-
pected, based on previous experience with this model, there
was 2+ reticulin fibrosis at study endpoint in all placebo-treated
animals that were analyzed (n = 3), whereas in three of four ani-
mals treated on the 120 mg/kg arm there was no evidence of re-
ticulin fibrosis. These findings indicate that efficacious treatment
of the polycythemia-vera like syndrome may result in reversion of
myelofibrosis (Figures 2Dj–2Dl).
Efficacy of TG101348 as Assessed by Flow Cytometry
and Hematopoietic Colony Formation
Comparative flow cytometric analysis was performed on spleno-
cytes or bone marrow of mice treated with TG101348 or pla-
cebo. There was an 2-fold decrease in JAK2V617F-positive
CD71-single-positive early erythroid precursors (p < 0.01) in
the bone marrow of animals at the 120 mg/kg dose comparedCancer Cell 13, 311–320, April 2008 ª2008 Elsevier Inc. 313
Cancer Cell
Efficacy of TG101348 in a Murine Model of PVwith vehicle. A similar reduction was observed in the number of
cells of the neutrophil/monocyte lineage that express both Gr1
and Mac1 markers that delineate these cells in mice in the
bone marrow or spleens at this drug dose. There were modest
effects observed on mature B cells when compared with control
(Figure 3A).
The potential effect of the drug on lymphopoiesis was difficult
to assess in the context of a fulminant myeloproliferative disease
after lethal irradiation for bone marrow transplantation. To better
understand the effects of TG101348, a cohort of three groups of
wild-type nonirradiated animals (n = 7) was treated concurrently
for 42 days by oral gavage with vehicle, 60 mg/kg or 120 mg/kg
of drug, respectively. Differential blood counts demonstrated
a slight reduction of total WBC and hematocrits for wild-type an-
imals in the 100 mg/kg treatment arm but within the normal range
(Table S3). With flow cytometric analysis we detected no effect
on T cell number in either the bone marrow or spleen of animals
treated with TG101348. However, we observed a statistically
significant reduction, albeit modest, in B cell number in the
bone marrow of JAK2V617F and the bone marrow and spleen
of wild-type animals, but not in other compartments. Thus, 42
days of treatment with TG101348 had no appreciable effect on
Figure 2. Survival and Response of JAK2V617F BM Transplant
Animals Treated with TG101348
(A) Kaplan-Meier survival plot showing death of six JAK2V617F-express-
ing mice in the placebo (n = 20), of one in the 60 mg/kg group (n = 20), and
normal life expectancy for the 120 mg/kg group treated with TG101348
(n = 20).
(B) 1.5-fold reduction in spleen weights in the 60 mg/kg group (p < 0.01),
and 4-fold reduction in the 120 mg/kg group (p < 0.001) compared to the
placebo-treated arm. The error bars represent the mean ± SD.
(C) Differential blood counts in JAK2V617F-expressing mice treated with
placebo, 60 mg/kg, and 120 mg/kg of TG101348.
(D) Histology of JAK2V617F mice treated with placebo, 60 mg/kg, or 120
mg/kg of TG101348 with representative sections of spleen displaying
complete effacement of normal splenic architecture ([Da]–[Dc], H&E)
with a prominent expansion of red pulp comprised of maturing myeloid el-
ements, erythroid elements, and clusters of megakaryocytes ([Dd]–[Df],
H&E stain). Liver sections from JAK2V617F placebo-treated mice dis-
played evidence of extramedullary hematopoiesis in a perivascular and si-
nusoidal distribution that was notably absent in 60 mg/kg and 120 mg/kg
of TG101348-treated mice ([Dg]–[Di], H&E). Moderately to marked dif-
fusely increased 2+ reticulin fibrosis in JAK2V617F placebo-treated
mice (n = 3) decreased to a 1+ reticulin fibrosis or was absent in 75% of
JAK2V617F-expressing mice treated with 120 mg/kg (n = 4) ([Dj]–[Dl],
reticulin stain).
T cell number. In addition, there was no reduction in cells
of the neutrophil/monocyte lineage that express both Gr1
and Mac1 markers. This observation indicates that the
drug has less inhibitory effect in wild-type hematopoietic
cells than in JAK2V617F-positive cells. (Figure 3B;
Figure S3A–S3C).
In the bone marrow, there was a marked dose-dependent
effect on the number of BFU-E with a reduction of 40% in the
60 mg/kg group compared with control and complete sup-
pression of BFU-E formation in the 120 mg/kg group. There
were minimal effects at either dose level among other
colony-forming units (Figure 3C). There were similar findings
in the spleen, in which there was abrogation of erythroid
colony-forming capacity at the 120 mg/kg dose compared to
control (p < 0.01), though there was less of an effect at the
60 mg/kg dose. In addition, in the spleen there was a reduction
in CFU-GM and CFU-M colony formation by 10- or 3-fold
at the 60 mg/kg or 120 mg/kg doses, respectively (p < 0.05)
that correlated with an overall reduction of colony-forming activ-
ity of 2-fold compared to vehicle-treated animals (Figure 3D).
Assessment of Surrogate Endpoints of Response
Conventional response criteria include assessment of complete
blood counts, histopathology including myelofibrosis, and as-
sessment of immunophenotypic and colony-forming unit re-
sponses. To determine which surrogate markers correlated
with these responses, we also assayed for disease burden using
quantitative genomic PCR for the presence of the integrated
JAK2V617F retrovirus, the ability of serum derived from treated
animals to inhibit growth of human BFU-E, and reduction of
phosphorylated Stat5 as assessed by flow cytometry.
Quantitative PCR for the JAK2V617F retrovirus was performed
on DNA derived from peripheral blood, bone marrow, and spleen
of treated and control animals at study endpoint. We observed
a dose-dependent reduction in genomic disease burden using314 Cancer Cell 13, 311–320, April 2008 ª2008 Elsevier Inc.
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Efficacy of TG101348 in a Murine Model of PVFigure 3. Assessment of Efficacy by Flow Cytometric Analysis and Hematopoietic Colony-Forming Capacity in Response to Treatment with
TG101348
(A) The bar graphs in the top row display staining of the average of the erythroid compartment of live JAK2V617F-expressing cells and demonstrate a 2.3-fold
decrease in the CD71 single-positive (p < 0.01) immature erythroid precursor population in bone marrow of animals treated with 120 mg/kg of drug and a 2.5-fold
decrease in ter119 single-positive more mature erythroid precursors (p < 0.01) in spleen. The bar graphs in the bottom row represent percentages of neutrophil/
monocyte cells expressing Gr1 and Mac1 treated with 120 mg/kg (p < 0.01).
(B) The bar graphs represent the hematopoietic compartment of PB, BM, and spleen of wild-type nonirradiated mice. Notably, no differences among the placebo
and both drug-treated groups for neutrophil/monocyte cells expressing Gr1 and Mac1 markers, T-lymphocytes, erythroid precursors, and B-lymphocytes in
spleens were detected, although a modest reduction of B-lymphocytes for both drug-treated groups was observed in BM. The error bars in (A) and (B) represent
the mean ± SD.
(C) Total numbers of BFU-E were decreased by 40% in the bone marrow of the 60 mg/kg group (p < 0.01) and absent in the bone marrow and spleens of the
120 mg/kg group (p < 0.01) after 42 days of treatment with TG101348 compared to placebo.
(D) Total numbers of CFU-GM and CFU-M of splenocytes were reduced at least 2.5-fold (p < 0.05).this metric, with ablation of hematopoietic cells containing the
JAK2V617F retrovirus at the 120 mg/kg dose (PB p < 0.001,
BM and Spl p < 0.01), with a more limited response at the 60
mg/kg dose level (Spl p < 0.05) (Figure 4A and Figure S4A). These
data indicate that TG101348 effectively reduces disease burden
in treated animals, and suggests that quantitative assessment
of JAK2V617F allele burden may be of value in monitoring
response to therapy.
JAK2V617F-positive MPD is also associated with the patho-
gnomonic finding of erythropoietin independent erythroid colony
formation (EEC) that offers an opportunity to assess functional
eradication of this population by JAK2 inhibitors. In the presence
of erythropoietin in vitro, we observed an5-fold or8.5-fold re-
duction of BFU-E derived from patients with PV at 300 or 600 nM
TG101348, respectively. Of note, in the absence of erythropoie-
tin, TG101348 showed increased potency, with nearly complete
inhibition of EEC formation at a concentration of 300 nM (Fig-
ure 4B). We next assessed inhibition of human EEC from PV
bone marrow by treatment with serum derived from drug-treated
mice. Serum was collected 2 hr after a dose of 60 mg/kg or 120
mg/kg, respectively, and added to methylcellulose cultures of
bone marrow cells from human PV patients with JAK2V617F.We observed abrogation of erythroid colonies scored at 7 days
at each dose level of TG101348 (Figure 4C).
We next assessed the potential value of measuring activation
status of signal transduction targets of JAK2V617F such as
STAT5 in monitoring response to therapy. We first characterized
the effect of TG101348 on signal transduction pathways acti-
vated by JAK2V617F in vivo using flow cytometry with phospho-
specific antibodies to STAT5, Erk or S6 kinase (S6K), an effector
of the PI3K/AKT pathway. Flow cytometry was used to isolate
disease-relevant hematopoietic progenitors derived from ani-
mals by gating on GFP+CD71+ immature erythroblasts, or
GFP+Mac1+Gr1+ myeloid cells that harbored the JAK2V617F
retrovirus. We assessed the activation state of signaling interme-
diates in cells starved of growth factors for 4 hr and then stimu-
lated with Interleukin 3 (IL3) and erythropoietin (EPO).
JAK2V617F expressing myeloid cells had comparable basal
levels of activation of Stat5, Erk, or S6K compared to wild-type
cells, but showed a marked relative increase in activation state
of these proteins after stimulation with IL3 and EPO
(Figure 5A). In contrast JAK2V617F expressing erythroid cells
had activated basal signaling levels, but upon cytokine stimula-
tion (IL-3 and EPO), the degree of phosphorylation furtherCancer Cell 13, 311–320, April 2008 ª2008 Elsevier Inc. 315
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eloid as well as erythroid with TG101348 resulted in a marked de-
crease in activation of Stat5 as assessed by staining with phos-
phospecific antibody. These data indicate that TG101348 is
capable of inhibiting phosphorylation of STAT5 and other effec-
tors of the JAK-STAT signaling pathway in relevant primary he-
matopoietic cells expressing JAK2V617F derived from animals.
We then tested whether flow cytometry could be used to mea-
sure pharmacodynamic response to therapy in treated animals
in vivo. Cells were harvested from animals 2 hours after treat-
ment with TG101348, sorted for the markers described above,
and immediately stained for phosphoStat5. We observed
a marked reduction in phosphorylated Stat5 and phosphorylated
S6K in GFP+CD71+ immature erythroblasts, as well as
GFP+Mac1+Gr1+ myeloid cells derived from TG101348 treated
versus vehicle control animals (Figure 5B; Figure S4B).
We also assayed activation state of Stat5 in BFU-E derived
from bone marrow of patients with polycythemia vera. After
growth of BFU-E for 7 days in methylcellulose cultures, individual
colonies were isolated and treated with TG101348 at a concen-
tration of 600 nM on glass slides. Immunofluorescence confocal
microscopy demonstrated a >90% reduction in phosphoStat5 in
treated cells versus controls (Figure 5C).
Taken together, these findings indicate that one or more ex-
perimental approaches may be of value in evaluating surrogate
endpoints for response in clinical trials of JAK2 inhibitors in
MPD, including (1) assessment of disease burden using quanti-
tative genomic PCR for the JAK2V617F disease allele, (2) func-
tional assessment of the EEC activity in treated patients, and
(3) flow cytometry using antibodies that delineate activation state
of signal transduction effectors of JAK2V617F.
DISCUSSION
JAK2V617F is an attractive therapeutic target in MPD, and there
is a substantial patient population that may benefit from
Figure 4. Evaluation of Surrogate End-
points of Response after TG101348 Treat-
ment
(A) Quantitative PCR for JAK2V617F retrovirus on
DNA from peripheral blood, bone marrow, and
spleen of treated and control animals at study
endpoint.
(B) TG101348 inhibits EEC formation of bone mar-
row (upper panel) and peripheral blood (lower
panel) of PV patients with and without erythropoi-
etin in a dose-dependent manner.
(C) Inhibition of erythroid colony formation of PV
bone marrow with mouse serum collected 2 hr af-
ter a dose of 60 mg/kg or 120 mg/kg. The error
bars in (A)–(C) represent the mean ± SD.
improved therapy that is considerably
larger than for related diseases such as
CML. Although there is evidence for ge-
netic heterogeneity among PV, ET, and
PMF(Levine et al., 2006) and the acquisi-
tion of JAK2V617F may be a secondary
event in at least some cases of sporadic and heritable MPD,
this single allele is associated with the majority of cases.
JAK2V617F or JAK2 exon 12 mutations appear to be present
in all cases of polycythemia vera, and JAK2V617F is present in
50% of cases of ET or PMF, respectively (Baxter et al., 2005;
James et al., 2005; Kralovics et al., 2005; Levine et al., 2005;
Scott et al., 2007). Exon 12 mutations appear to occur more fre-
quently in individuals whose clinical phenotype is characterized
by polycythemia with a trend toward normal leukocyte and plate-
let counts. This observation in humans and data from the mouse
model suggest that the exon 12 mutations confer a relative pre-
dilection for erythroid cell-fate determination compared with the
exon 14 mutation. Although a solved structure is not available,
predicted structures place the exon 12 and exon 14 mutations
as physically proximate. JAK2V617F and related alleles each
confer factor-independent growth to hematopoietic cell lines,
and murine models of disease recapitulate many of the features
of human MPD (Wernig et al., 2006; Lacout et al., 2006; Zaleskas
et al., 2006). In these settings, JAK2 inhibition induces apoptotic
cell death, indicating that, like other oncogenic tyrosine kinases,
JAK2V617F confers dependence on JAK signaling to the resi-
dent hematopoietic progenitor cell. Thus, a safe and efficacious
small-molecule inhibitor of JAK2 might be expected to have ther-
apeutic benefit in these cases, analogous to that observed in sta-
ble phase BCR-ABL-positive CML patients treated with imatinib.
Furthermore, cellular cytotoxicity assays with novel alleles dis-
covered in the remainder of MPD cases, such as MPLW515L/K
that is associated with 2%–5% of ET or PMF, are also sensitive
to inhibition with JAK2 inhibitors (Pikman et al., 2006).
Our data indicate that the JAK2 selective inhibitor TG101348
has potential for efficacious treatment of JAK2V617F-associated
MPD. We utilized a murine model in which disease was fully es-
tablished prior to initiation of therapy and demonstrated dose-
dependent responses to therapy. We designed these studies
to accommodate the long half-life of red cells in mice (40–50
days) by treating animals for 42 days with TG101348. Although316 Cancer Cell 13, 311–320, April 2008 ª2008 Elsevier Inc.
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Transduction Pathways in Response to
Therapy with TG101348
(A) Bone marrow of wild-type (WT) or JAK2V617F
were harvested then starved for 4 hr. Cells were in-
cubated with indicated inhibitors for 15 min and
then stimulated with IL-3 and EPO for 10 min be-
fore fixation and staining. Cells were then analyzed
by flow cytometry and gated for CD71 or Mac-1/
Gr-1 double-positive cells. (A) and (B) are repre-
sentative of 3–5 independent experiments.
(B) Bone marrow from either WT or transplanted
mice with JAK2V617F were treated with or without
TG101348 120 mg/kg and fixed immediately and
stained with indicated antibodies. Levels of phos-
phorylation were determined using flow cytometry.
(C) Human PV BFU-E colonies were picked after 14
days in culture and then put on slides. Indicated
cells were treated with TG101348 for 15 min and
then fixed and stained for pSTAT5 (red) and DAPI
(blue). Images were taken and overlaid using a con-
focal immunofluorescence microscope and a rep-
resentative image chosen for display.time and labor intensive, such an approach enables accurate as-
sessment of red cell response, in addition to providing insights
into potential toxicities associated with long-term therapy. We
observed that the drug was well tolerated, with statistically sig-
nificant reductions in HCT and WBC, with concomitant evidence
of response by histopathologic analysis, including attenuation of
reticulin fibrosis, flow cytometric evidence for reduction in ery-
throid and myeloid progenitors, and reduction of colony-forming
activity of these populations in vitro.
Thus, these in vivo data suggest that there is promise for this
approach to treatment of JAK2V617F-positive MPD. In addition,
there is a strong precedent for use of small-molecule tyrosine ki-
nase inhibitors in BCR-ABL-positive CML, PDGFRB-rearranged
CMML, PDGFRA-rearranged CEL, gastrointestinal stromal cell
tumors, and non-small-cell lung carcinomas(Apperley et al.,
2002; Cools et al., 2003; Druker et al., 2001a, 2001b; Lynch
et al., 2004; Pao et al., 2004; van Oosterom et al., 2001). How-
ever, there are particular challenges in applying this strategy
for treatment of JAK2V617F-positive MPDs.
PV, ET, and PMF are relatively indolent diseases that progress
to AML at a lower frequency than CML, estimated to be 5%
over the lifetime of affected individuals. Furthermore, although
PV, ET, and PMF are associated with potentially serious and/or
fatal complications including thrombosis and hemorrhage, these
are also relatively infrequent (Harrison et al., 2005). Thus, a JAK2
inhibitor for treatment of PV, ET, or PMF should be safe for pro-
longed treatment, and strategies need to be developed that will
allow for reliable prediction and monitoring of response to ther-
apy and identification of surrogate endpoints for response that
will enable expeditious testing of JAK2 inhibitors.
As regards safety, in addition to the standard toxicities, atten-
tion has focused on potential off-target effects of JAK2 inhibitors
on JAK3. PV, ET, or PMF patients are not immunocompromised
as a consequence of their primary disease. If one assumes that,
as for BCR-ABL-positive CML, long-term therapy is likely to be
required for maintenance of remission, any effect on T cell num-
ber of function due to JAK3 inhibition could be deleterious in this
patient population. In this light, efforts to develop JAK2 inhibitorsthat are highly selective for JAK2 compared to JAK3, such as
TG101348, are warranted.
Prediction and monitoring of response to therapy will also be
of central importance based on the paradigm for treatment of
BCR-ABL-positive disease, where it is now appreciated that mo-
lecular assessments of disease burden and of initial response to
therapy are highly predictive of long-term responses. To this
end, a need for reliable assays that measure disease burden
can be anticipated in clinical trials of JAK2 inhibitors. Our find-
ings indicate that genomic copy burden correlates with clinical
response to disease, and such measurements should be consid-
ered as part of clinical trial design for treatment in humans. In ad-
dition, in PV, ET, or PMF with JAK2V617F, in contrast with CML,
there is an advantage of assays for EEC (Prchal and Axelrad,
1974) that provides an opportunity for functional assessment
of the malignant clones to therapy. Our data indicate that such
assays may also be of value in clinical trials. Finally, assessment
of the activation state of STAT5, or other effectors of activated
JAK2 such as ERK or S6K, may be of value as pharmacodynamic
marker of response. These type of surrogate endpoints for re-
sponse have been validated in the context of CML (Prchal and
Axelrad, 1974) and may enable more rapid assessment of the
clinical potential of JAK2 inhibitors in smaller trials with fewer
number of patients.
This animal model does not address the potential of JAK2 in-
hibitors for treating thrombocythemia associated with these
MPD, in that thrombocytosis is not observed in the JAK2V617F
murine model (Wernig et al., 2006). However, MPLW515L does
induce robust thrombocytosis in the murine bone marrow trans-
plant model and is sensitive to inhibition with JAK2 inhibitors, so
this system may prove suitable for assessing platelet responses
(Pikman et al., 2006).
Lastly, these findings raise the question of which patient pop-
ulation should be tested initially for efficacy and safety of JAK2
inhibitors. Although there are several potential approaches, it
would seem most appropriate to treat individuals with severe
manifestations of disease that are currently refractory to conven-
tional therapies, such as progressive myelofibrosis. In this light, itCancer Cell 13, 311–320, April 2008 ª2008 Elsevier Inc. 317
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ease, JAK2 inhibition resulted in attenuation of myelofibrosis.
EXPERIMENTAL PROCEDURES
Reagents
TG101348 (N-tert-butyl-3-(5-methyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)
pyrimidin-4-ylamino)benzenesulfonamide) was synthesized by TargeGen Inc.
(San Diego, CA, USA). Stock solutions were made in dimethylsulfoxide
(DMSO), and subsequently diluted in RPMI-1640 medium for use. Anti-
phospho-Stat5 (Tyr694) (polyclonal) and anti-Stat5 (polyclonal) were pur-
chased from Cell Signaling (Beverly, MA, USA), and anti-b-actin (monoclonal)
was purchased from Novus Biologicals Inc. (Littleton, CO, USA).
Cell Lines
Human erythroleukemic cell line (HEL) was purchased from American Type
Culture Collection (Rockville, MD, USA) and cultured in RPMI-1640 medium
(GIBCO BRL, Gaithesburg, MD, USA), supplemented with 10% fetal bovine
serum (FBS) penicillin at 37C and 5% CO2. The V617F mutation was intro-
duced by site-directed mutagenesis (QuikChange kit, Stratagene, La Jolla,
CA) into a plasmid that carries the full length human JAK2 cDNA (Invitrogen,
Carlsbad, CA). Once confirmed by DNA sequencing, the JAK2V617F cDNA
was subcloned into a retroviral vector (Stratagene). Recombinant retroviral
particles were produced in HEK293 cells and subsequently transduced into
Ba/F3 cells. Permanently transduced Ba/F3 cells that express human
JAK2V617F were selected and maintained by 1 mg/ml G418.
IC50 Determinations by Cell-free Kinase Activity Assays
IC50 values for TG101348 were determined commercially using the InVitrogen
(Carlsbad, CA, USA) kinase profiling service for a 223 kinase screen that in-
cluded JAK2 and JAK2V617F or Carna Biosciences (Kobe, Japan) for the
screen of all Janus kinase family members including JAK1 and Tyk2. ATP con-
centration was set to approximately the Km value for each kinase.
XTT Assay for Cell Proliferation, Apoptosis, and DNA
Laddering Assay
Approximately 2 3 103 cells were plated into microtiter-plate wells in 100 ml
RPMI-1640 growth media with indicated concentrations of inhibitor. Following
72 hr incubation with TG101348, 50 ml of XTT dye (Roche; Basel, Switzerland)
were added to each well and incubated for 4 hr in a CO2 incubator. The colored
formazan product was measured by spectrophotometry at 450 nm with cor-
rection at 650 nm. The concentration in which 50% of the effect (i.e., inhibition
of proliferation) is observed (IC50) was determined using the GraphPad Prism
4.0 software. All experiments were performed in triplicate, and the results were
normalized to growth of untreated cells. Induction of apoptosis of EpoBa/F3
JAK2V617F, Ba/F3p210, HEL, and K562 cells was determined by DNA frag-
mentation with DMSO and increasing concentrations of inhibitor.
Western Blot Analysis
Cells were treated with DMSO and increasing concentrations of inhibitor for
4 hr in RPMI-1640 before collected in 13 Cell Lysis Buffer (Cell Signaling, Bev-
erly, MA, USA), containing 1 mM PMSF, and protease inhibitor cocktail tablets
(Roche). Protein lysates were quantified with Pierce Biotechnology BCA assay
(Rockford, IL, USA). Similar protein amounts were mixed with Laemmli sample
buffer (Bio-Rad Laboratories, Hercules, CA, USA) plus b-mercaptoethanol,
boiled for 5 min, and separated on a 4%–15% Tris-HCL gradient electropho-
resis gel (Bio-Rad Laboratories). Gels were blotted onto a 0.45 mm nitrocellu-
lose membrane (Bio-Rad), which was blocked in 5% nonfat dry milk and incu-
bated with primary antibodies in either blocking solution or 5% BSA. The
membranes were subsequently incubated with a mixture of donkey anti-rabbit
IgG conjugate with infrared fluorophore (700 nm emission, LICOR) and goat
anti-mouse IgG conjugated with infrared fluorophore (800 nm emission). Fol-
lowing washing with PBS, the membranes were scanned on a LICOR Odyssey
scanner to detect total (red) and phospho-STAT5 (green) proteins.318 Cancer Cell 13, 311–320, April 2008 ª2008 Elsevier Inc.Pharmacokinetic Properties of TG101348 in C57Bl/6 Mice
Fifty-four C57Bl/6 mice were divided into 3 groups with 18 mice at each dose
level. Single oral doses of 30, 100, and 200 mg/kg were administered. Animals
were allowed food and water ad libitum. Composite sampling was employed
to generate plasma concentration-time profiles for TG101348 over the follow-
ing time course (n = 3/ time point): 0.5, 1, 3, 5, 7, and 24 hr postdose. Plasma
samples were processed by addition of a 2-fold excess of acetonitrile contain-
ing internal standard followed by centrifugation. The supernatants were iso-
lated for analysis. Processed plasma samples were quantitated by LC/MS/
MS against external calibration standards prepared in naive mouse plasma.
Matrix calibration standards and quality control (QC) samples were prepared
by adding stock solutions of TG101348 into blank mouse plasma. The concen-
trations of the external calibration curve ranged from 1.9 to190 nM. Study sam-
ples above the upper calibration limit were diluted into the calibration range
with blank mouse plasma and reanalyzed.
The LC/MS/MS system consisted of a Sciex API3000 triple quadrupolar
mass spectrometer (MDS Sciex), an Agilent 1100 HPLC system (Agilent Tech-
nologies, Inc), and a CTC autosampler (Leap Technologies). The LC separa-
tions were performed on a Zorbax SB 753 2.1 mm and a 3.5 mm reverse phase
HPLC column (Agilent Technologies, Inc). The column temperature was kept at
40C. Mobile phase A consisted of 0.1% formic acid in water, and mobile
phase B consisted of 0.1% formic acid in acetonitrile. The flow rate was
kept constant at 0.40 ml/min. Following a 20 ml sample injection, mobile B
was held at 10% for 0.5 min followed by a linear increase to 90% mobile phase
B over 1.5 min. The mass spectrometric detection of TG101348 and internal
standard was achieved using electrospray ionization operating in positive
ionization mode. The molecular ion transitions were monitored in MRM mode
for TG101348 and internal standard.
Murine Model and Analysis of Mice after Treatment
with TG101348
The murine BM transplant model was generated and analyzed exactly as pre-
viously described (Wernig et al., 2006). Briefly, C57BL/6 mice (Taconic, Ger-
mantown, NY) were intravenously injected with 1 3 106 whole bone marrow
expressing JAK2V617F. Full development of disease was assessed with differ-
ential peripheral blood counts at day 26 after bone marrow transplantation.
TG101348 was administered by oral gavage twice daily (b.i.d.) at 60 mg/kg,
120 mg/kg, or placebo from day 28 on for 42 days. Differential blood counts
were assessed by retro-orbital nonlethal eyebleeds using EDTA glass capillary
tubes before study initiation, during the study, and at study endpoints. C57/Bl6
mice were sacrificed at study endpoint or at times indicated based on an
IUCAC-approved protocol that includes assessment of morbidity by > 10%
loss of weight, scruffy appearance, lethargy, and/or splenomegaly extending
across the midline. For histopathology, tissues were fixed in 10% neutral buff-
ered formalin, embedded in paraffin, and stained with hematoxylin and eosin
or, to assess for fibrosis, stained with reticulin. Images of histological slides
were obtained on a Nikon Eclipse E400 microscope (Nikon, Tokyo, Japan)
equipped with a SPOT RT color digital camera model 2.1.1 (Diagnostic Instru-
ments, Sterling Heights, MI). Images were analyzed in Adobe Photoshop 6.0
(Adobe Systems, San Jose, CA). For flow cytometry, cells were washed in
PBS, washed in 2% fetal bovine serum, blocked with Fc-Block (BD PharMin-
gen, San Diego, CA) for 10 min on ice, and stained with monoclonal antibodies
in PBS and 2% FCS for 30 min on ice. Antibodies used were allophycocyanin
(APC)-conjugated ter119, Gr-1, CD4, and B220 and phycoerythrin (PE)-conju-
gated, Mac1, CD8 (all 1:200), and CD71(1:100) rat anti-mouse (BD PharMin-
gen). After washing, cells were resuspended in PBS and 2% FCS containing
0.5 mg/ml 7-amino-actinomycin D (7-AAD) (BD PharMingen) to allow discrim-
ination of nonviable cells. Flow cytometry was performed on a FACS Calibur
cytometer (BD Biosciences, San Jose, CA), at least 10,000 events were
acquired, and data were analyzed using FloJo software. The results are
presented as graphs and representative dot plots of viable cells selected on
the basis of scatter and 7-AAD staining.
Colony Assays
To assess colony-forming capacity during in vivo drug treatment, 1 3 105 BM
and spleen cells from JAK2V617F mice treated with 60 mg/kg or 120 mg/kg of
drug or placebo were harvested at study endpoint, plated in duplicate in meth-
ylcellulose (M3434, Stem Cell Technologies) according to the manufacturer’s
Cancer Cell
Efficacy of TG101348 in a Murine Model of PVprotocol, and counted after 7 days in culture. For colony assays with human
MPD patient samples, whole bone marrow and peripheral blood of PV and
ET patients positive for JAK2V617F, 1 3 105 cells/ml of bone marrow as well
as peripheral blood were plated in methylcellulose (H4534 Stem Cell Technol-
ogies) without Epo or supplemented with 3 units of Epo (Cell Sciences). For hu-
man colony assays incubated with mouse serum, serum was collected from
animals 2 hr postdosing with 60 mg/kg, 120 mg/kg, or placebo.
DNA Isolation and Measurement of JAK2V617F Virus
Sequence to Detect Genomic Disease Burden
by Quantitative Genomic PCR
Genomic DNA was isolated from peripheral blood, bone marrow, and spleen of
drug-treated animals using the QIAamp DNA Blood Mini kit (QIAGEN). Quan-
titative PCR was performed using primers for retroviral sequence of
JAK2V617F MSCV-IresGfp, 50-AGG CGC CG AAT TAG ATC T and 30-GAG
GTT GCC TCC ATT TCT GTC. Primers were designed using Primer Express
software (Applied Biosystems). Sample DNA was amplified with Taqman 23
PCR master mix or 23 SYBR green PCR master mix (Applied Biosystems). Re-
actions were run in duplicate with 2.5 ml cDNA in a total reaction volume of 25 ml
using an ABI Prism 7700 Sequence Detection System (Applied Biosystems).
Ratio of the means of relative copy number of the JAK2V617F MSCV-IresGfp
virus sequence was calculated relative to Gapdh using a standard curve
technique.
Flow Cytometric Staining of Intracellular Phosphorylated STAT5,
ERK, and S6K
Freshly isolated BM from wild-type JAK2- and JAK2V617F-transplanted ani-
mals was harvested 3 hr after dosing with TG101348 120 mg/kg as control pla-
cebo-treated wild-type JAK2 and JAK2V617F bone marrow was used, fixed
immediately with 2% PFA (Polysciences, Inc., Warrington, PA), and permeabi-
lized with 90% ice-cold methanol or cultured for 4 hr in RPMI + 1% BSA at
37C stimulated with IL-3, SCF, and IL-6 (StemCell technologies) or EPO
(Cell Sciences) and treated with TG101348 (0.6 mM). Staining was performed
as previously described (Krutzik and Nolan, 2003). Briefly, cells were incubated
with anti-phospho-STAT5 PE (phycoerythin) (BD pharmingen) 1:50, anti-phos-
pho-ERK 1:100 (Cell signaling), and anti-phospho-S6 1:100 (Cell signaling), re-
spectively. Following a final wash, the samples were sorted by flow cytometry
on a FACS Aria and analyzed using FloJo software. Human cells were analyzed
on a ZEISS LSM510-META upright laser confocal microscope using 623mag-
nification and analyzed with LSM software from Zeiss.
Statistical Analysis, Animal Studies, and Patient
Sample Collection
Pooled data are displayed as mean ± SD. To assess statistical significance
among the two groups, the paired Student’s t test was used. Animal studies
were conducted using an IUCAC-approved animal protocol at our institution.
In addition, studies involving human material were obtained under auspices of
informed consent, and the study was approved by Institution Review Board.
SUPPLEMENTAL DATA
The Supplemental Data include four supplemental figures and three supple-
mental tables and can be found with this article online at http://www.
cancercell.org/cgi/content/full/13/4/311/DC1/.
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